醫藥和生技領域的資產收購協議（2019-2026 年）

利用基於 891 個真實案例的交易數據，了解製藥和生技公司如何取得產品、技術、業務資產和特許權使用費權益。

《醫藥和生物技術領域的資產收購協議》提供了全球生命科學產業 891 項資產收購交易的全面資訊。

資產收購為公司提供了一種替代收購整個業務的方式，使買家能夠獲得與其策略或投資組合目標相輔相成的特定產品、技術、智慧財產權、業務資產或特許權使用費權益。

對賣家而言，資產交易可以是一種在維持整體業務的同時，將單一項目、技術或非核心資產貨幣化的手段。

本報告考察了這些交易在製藥和生物技術領域是如何被利用的，哪些公司最活躍，正在收購哪些類型的資產，以及可以從披露的財務條款和公開的合約文件中檢驗什麼。

這份報告不僅列出了交易，還幫助讀者了解收購了什麼、誰在買賣資產、交易的結構是什麼、對價是如何分配的，以及類似的協議實際上是如何談判的。

本報告為業務發展、企業發展、許可、投資組合策略、法律、交易和競爭情報分析團隊提供可操作的資訊來源和基準資源，以評估資產收購和剝離機會。

了解資產收購交易的整體狀況。

本報告分析了2019年至2026年的資產收購交易，內容包括：

• 資產收購活動的年度趨勢
• 交易時的發展階段
• 產業部門
• 治療區域
• 技術類型
• 最活躍的資產收購交易商
• 根據已披露的交易金額，主要交易
• 進行資產收購交易的策略性原因
• 資產收購活動的趨勢

本分析涵蓋的交易如下：

• 企業資產
• 產品資產
• 特許權資產
• 技術資產
• 這使用戶能夠了解不同類型的生命科學資產是如何被收購的，以及交易活動集中在哪些領域。
• 了解資產購買協議的結構
• 在資產收購交易中，必須明確界定轉讓的資產是什麼，與這些資產相關的權利和義務是什麼，以及買賣雙方各自應承擔的責任是什麼。

本報告提供以下信息，幫助使用者檢驗以下方面：

• 待轉移的資產和權利
• 智慧財產權的所有權和轉讓
• 產品和技術權利
• 特許權使用費和經濟利益
• 開發和商業化義務
• 技術和知識轉移
• 製造和供應安排
• 已承擔和已保留的負債
• 過渡安排
• 陳述與保證
• 結項條件
• 買賣雙方之間的持續義務
• 揭露時的金錢補償
• 合約終止及其他交易條款
• 這些案例研究在評估、建構或協商資產收購和出售交易時可作為有用的參考資料。
• 資產收購的財務指標
• 本報告提供了與個別資產收購交易相關的已揭露財務資訊。

根據交易的具體情況，可能包括以下內容：

• 預付款或成交時付款
• 延期付款
• 發展里程碑
• 監管里程碑
• 商業里程碑
• 特許權使用費協議
• 有條件考慮
• 其他已揭露的財務義務
• 重大資產收購交易也按其揭露的交易價值進行排名，使用戶能夠識別重要的領先並調查其底層結構。
• 在考慮類似資產交易的潛在結構和經濟效益時，這些資訊可提供有用的背景資訊。
• 識別活躍的買家和賣家
• 本報告重點介紹了資產收購交易中最活躍的 25 家公司，深入分析了那些反覆收購或剝離醫藥和生技資產的公司。

交易歷史記錄可協助使用者識別以下內容：

• 積極收購產品和技術的公司
• 企業出售非核心資產
• 準備出售資產的潛在買家
• 競爭對手加強特定產品組合
• 公司進入新的治療和技術領域
• 相關過往交易範例
• 因此，本報告對企​​業發展、投資組合策略、業務發展和競爭情報分析特別有用。
• 從實際資產購買協議中吸取經驗
• 本報告提供了公開可取得的基礎資產購買協議文件的途徑。

這些合約揭示了僅憑交易公告無法獲得的詳細信息，使用戶能夠檢驗公司如何記錄有關以下事項的條款：

• 待轉移的資產和智慧財產權
• 購買價格
• 里程碑和特許權使用費義務
• 陳述與保證
• 可承擔的負債和可排除的負債
• 開發和商業化義務
• 技術轉移
• 過渡措施
• 結項條件
• 合約終止及後續義務
• 對於評估和準備資產交易的團隊來說，獲取實際的合約措辭可以讓他們深入了解類似交易的實際結構。
• 綜合資產收購交易目錄
• 本報告包含一個涵蓋 891 項資產收購交易的綜合目錄，使用戶能夠找到與其自身資產、技術和策略目標相關的交易。

在以下條件下可以查看交易記錄：

• 公司
• 治療區域
• 技術類型
• 合約揭露狀態
• 每筆交易都與其底層交易記錄相關聯，從而可以存取詳細的交易資訊和相關的合約文件（如有）。
• 誰該使用這份報告？
• 企業發展與併購團隊
• 這可以識別過去的資產收購案例、當前活躍的買家和賣家以及相關的交易結構。
• 業務拓展與授權團隊
• 我們評估資產收購作為許可的替代方案，並確定正在收購或出售相關產品或技術的公司。
• 投資組合策略團隊
• 我們將了解每家公司如何取得策略性資產以及如何將非核心業務變現或剝離。
• 準備出售資產的公司
• 我們確定潛在的收購目標，並調查涉及類似產品、技術或開發階段的類似交易。
• 法律及交易團隊
• 我們仔細審查實際的合約結構和公開的合約條款，以協助進行實質審查、合約起草和談判。
• 競爭資訊分析團隊
• 我們追蹤競爭對手如何利用資產收購和剝離來重組其產品線、投資組合和策略重點。
• 我們將市場整體資訊轉化為公司專屬洞察。
• 符合資格的客戶除了收到報告外，還將收到 Current Partnering 提供的客製化合作夥伴簡報。
• 本簡報將說明有關資產收購的基礎信息，並根據您的業務、產品、技術或交易目標量身定做。
• 如有需要，我們可以提供相關的類似交易、潛在買家和賣家、競爭對手的收購活動、交易結構、財務基準、合約見解以及其他專門為您情況選擇的資訊。
• 請索取樣本或聯絡 Current Partnering 討論本報告的內容以及我們是否可以為貴公司提供客製化分析。

目錄

執行摘要

第1章：引言

第2章：資產收購交易趨勢

• 介紹
• 已購資產類型
• 資產收購交易趨勢
• 簽訂資產收購夥伴關係協議的原因
• 資產收購交易的未來

第3章：資產收購交易結構概述

• 介紹
• 資產收購協議的結構

第4章：重大資產收購

• 介紹
• 按價值排名的前幾大資產收購交易

第5章：資產收購交易最活躍的25家公司

• 介紹
• 最積極參與資產收購交易的25家公司

第6章 資產收購交易（包括合約清單）

• 介紹
• 資產收購涉及合約。
• 特價優惠列表
• 交易目錄 - 公司資產收購交易 (AZ)
• 交易目錄 - 按治療領域分類的資產收購交易
• 交易目錄 - 按技術類型分類的資產收購交易
• 關於 Biopharma Research Ltd.
• Current Partnering
• 目前合約
• 最新報告標題

Understand how pharmaceutical and biotechnology companies acquire products, technologies, business assets and royalty interests using intelligence from 891 real-world transactions.

Asset Purchase Deals in Pharmaceuticals and Biotechnology provides comprehensive intelligence on 891 asset purchase deals across the global life sciences industry.

Asset acquisitions provide companies with an alternative to acquiring an entire business, enabling buyers to secure specific products, technologies, intellectual property, business assets or royalty interests that complement their strategic and portfolio objectives.

For sellers, asset transactions can provide a route to monetize individual programs, technologies or non-core assets while retaining the wider business.

The report examines how these transactions are being used across the pharmaceutical and biotechnology sectors, which companies are most active, what types of assets are being acquired and what can be learned from disclosed financial terms and publicly available contract documents.

Rather than simply identifying transactions, the report helps users understand what is being acquired, who is buying and selling assets, how transactions are structured, how consideration is being allocated and how comparable agreements have been negotiated in practice.

It provides a practical intelligence and benchmarking resource for business development, corporate development, licensing, portfolio strategy, legal, transaction and competitive intelligence teams evaluating asset acquisition or divestment opportunities.

Understand the asset purchase deal landscape

The report analyzes asset purchase dealmaking from 2019 to 2026, including:

• Trends in asset purchase activity by year
• Phase of development at the time of transaction
• Industry sector
• Therapy area
• Technology type
• Most active asset purchase dealmakers
• Leading transactions by disclosed value
• Strategic reasons for undertaking asset purchase transactions
• How asset acquisition activity is evolving

The analysis covers transactions involving:

• Business assets
• Product assets
• Royalty assets
• Technology assets
• This enables users to understand how different types of life science assets are being acquired and where transaction activity is concentrated.
• Understand how asset purchase agreements are structured
• Asset purchase transactions require precise definition of what is being transferred, which rights and obligations accompany the assets and what responsibilities remain with the buyer and seller.

The report provides intelligence to help users examine areas including:

• Assets and rights being transferred
• Intellectual property ownership and assignment
• Product and technology rights
• Royalty and economic interests
• Development and commercialization obligations
• Technology and know-how transfer
• Manufacturing and supply arrangements
• Assumed and retained liabilities
• Transition arrangements
• Representations and warranties
• Closing conditions
• Ongoing obligations between buyer and seller
• Financial consideration where disclosed
• Termination and other transaction provisions
• These real-world examples provide useful reference points when evaluating, structuring or negotiating asset acquisition and divestment transactions.
• Benchmark asset purchase financials
• The report provides access to disclosed financial information associated with individual asset purchase transactions.

Depending on the transaction, this can include:

• Upfront or closing consideration
• Deferred payments
• Development milestones
• Regulatory milestones
• Commercial milestones
• Royalty arrangements
• Contingent consideration
• Other financial commitments where disclosed
• Leading asset purchase transactions are also ranked by disclosed deal value, enabling users to identify significant precedent deals and investigate their underlying structures.
• This intelligence provides useful context when considering the potential structure and economics of comparable asset transactions.
• Identify active buyers and sellers
• The report profiles the Top 25 most active asset purchase dealmakers, providing insight into companies repeatedly acquiring or divesting pharmaceutical and biotechnology assets.

Transaction histories can help users identify:

• Companies actively acquiring products and technologies
• Organizations divesting non-core assets
• Potential buyers for assets being prepared for sale
• Competitors strengthening particular portfolios
• Companies entering new therapeutic or technology areas
• Relevant precedent transactions
• This makes the report particularly useful for corporate development, portfolio strategy, business development and competitive intelligence.
• Learn from real-world asset purchase contracts
• Where publicly available, the report provides access to underlying asset purchase contract documents.

These agreements can reveal considerably more detail than transaction announcements alone, enabling users to examine how companies have documented provisions relating to:

• Assets and intellectual property transferred
• Purchase consideration
• Milestone and royalty obligations
• Representations and warranties
• Assumed and excluded liabilities
• Development and commercialization obligations
• Technology transfer
• Transition arrangements
• Closing conditions
• Termination and continuing obligations
• For teams evaluating or preparing an asset transaction, access to real agreement language provides valuable insight into how comparable deals have been structured in practice.
• Comprehensive asset purchase deal directory
• The report includes a comprehensive directory of 891 asset purchase deals, enabling users to identify transactions relevant to their own assets, technologies and strategic objectives.

Deals can be reviewed by:

• Company
• Therapy area
• Technology type
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Corporate Development and M&A teams
• Identify precedent asset acquisitions, active buyers and sellers, and relevant transaction structures.
• Business Development and Licensing teams
• Evaluate asset purchase as an alternative to licensing and identify companies acquiring or divesting relevant products and technologies.
• Portfolio Strategy teams
• Understand how companies are acquiring strategic assets and monetizing or divesting non-core programs.
• Companies Preparing Assets for Sale
• Identify potential acquirers and investigate comparable transactions involving similar products, technologies or development stages.
• Legal and Transaction teams
• Review real-world agreement structures and publicly available contract language to support due diligence, drafting and negotiation.
• Competitive Intelligence teams
• Track how competitors are using asset acquisitions and divestments to reshape pipelines, portfolios and strategic focus.
• Turn market-wide intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying asset purchase intelligence to the customer's own business, products, technologies or transaction objectives.
• Depending on requirements, this can include relevant comparable transactions, prospective buyers or sellers, competitor acquisition activity, deal structures, financial benchmarks, contract insights and other intelligence selected specifically for the client's situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in asset purchase dealmaking

• 2.1. Introduction
• 2.2. Types of assets purchased
• 2.3. Trends in asset purchase deals
  • 2.3.1. Asset purchase dealmaking by year
  • 2.3.2. Asset purchase dealmaking by phase of development
  • 2.3.3. Asset purchase dealmaking by industry sector
  • 2.3.4. Asset purchase dealmaking by therapy area
  • 2.3.5. Asset purchase dealmaking by technology type
  • 2.3.6. Asset purchase dealmaking by most active company
• 2.4. Reasons for entering into asset purchase partnering deals
  • 2.4.1. Business assets
  • 2.4.2. Product assets
  • 2.4.3. Royalty assets
  • 2.4.4. Technology assets
• 2.5. The future of asset purchase deals

Chapter 3 - Overview of asset purchase deal structure

• 3.1. Introduction
• 3.2. Asset purchase agreement structure

Chapter 4 - Leading asset purchase deals

• 4.1. Introduction
• 4.2. Top asset purchase deals by value

Chapter 5 - Top 25 most active asset purchase dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active asset purchase dealmakers

Chapter 6 - Asset purchase deals including contracts directory

• 6.1. Introduction
• 6.2. Asset purchase deals with contracts
• Deal directory
• Deal directory - Asset purchase dealmaking by companies A-Z
• Deal directory - Asset purchase dealmaking by therapy area
• Deal directory - Asset purchase dealmaking by technology type
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of assets purchased
• Figure 2: Trends in asset purchase deal announcements
• Figure 3: Asset purchase deals signed at each phase of development
• Figure 4: Asset purchase deals by industry sector
• Figure 5: Asset purchase deals by therapy area
• Figure 6: Asset purchase deals by technology type
• Figure 7: Top 25 most active asset purchase dealmakers
• Figure 8: Top asset purchase deals by value
• Figure 9: Most active asset purchase dealmakers